Pre-Clinical Characterization of Dacomitinib (PF-00299804), an Irreversible Pan-ErbB Inhibitor, Combined with Ionizing Radiation for Head and Neck Squamous Cell Carcinoma

• Justin P. Williams,

  Affiliation Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada

  ⨯
• Inki Kim,

  Affiliation Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea

  ⨯
• Emma Ito,

  Affiliation Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada

  ⨯
• Wei Shi,

  Affiliation Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada

  ⨯
• Shijun Yue,

  Affiliation Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada

  ⨯
• Lillian L. Siu,

  Affiliations Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada, Division of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada

  ⨯
• John Waldron,

  Affiliation Department of Radiation Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada

  ⨯
• Brian O'Sullivan,

  Affiliation Department of Radiation Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada

  ⨯
• Kenneth W. Yip,

  Affiliation Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada

  ⨯
• Fei-Fei Liu

  * E-mail: Fei-Fei.Liu@rmp.uhn.on.ca

  Affiliations Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada, Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada, Department of Radiation Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada

  ⨯